December 29, 2025

HER2-Positive Early Breast Cancer: Trastuzumab Deruxtecan Moves Into Earlier Clinical Settings

Two pivotal studies of fam-trastuzumab deruxtecan-nxki (T-DXd) in early HER2-positive breast cancer suggest this antibody-drug conjugate (targeting the HER2 protein) may be moving into the curative se...

The ASCO Post

December 23, 2025

Rare Disease Reanalysis Ended Our 5-Year Wait

In conversation with the clinician who developed the proactive exome reanalysis approach, and the mother whose child benefited from it

The Pathologist

December 22, 2025

Statins and Glaucoma

Taiwanese study reopens old debate on the links between statin use and POAG risk

The Ophthalmologist

December 19, 2025

Data Published on Incidence of Immune Checkpoint Inhibitor–Associated ITP

Valuable information has been published about a rare but serious complication of cancer immunotherapy—immune checkpoint inhibitor–associated immune thrombocytopenia—providing the first large-scale des...

The ASCO Post

December 19, 2025

Chemotherapy-Free Regimen Improves Outcomes in Newly Diagnosed Patients With Ph-Positive ALL

Initial results from the phase III GIMEMA ALL2820 trial demonstrated that a front-line, chemotherapy-free regimen combining the tyrosine kinase inhibitor ponatinib and the bispecific T-cell engager bl...

The ASCO Post

December 19, 2025

KEYNOTE-905: Perioperative Immunotherapy Regimen Active in Cisplatin-Ineligible MIBC

A perioperative regimen of enfortumab vedotin-ejfv plus pembrolizumab significantly improved survival and pathologic complete response rates compared to radical cystectomy alone in patients with muscl...

The ASCO Post

December 19, 2025

From Cough to Clarity: Expanding the Respiratory Testing Toolkit

Is it time to expand the menu of testing options for respiratory infections?

The Pathologist

December 19, 2025

Europe’s Hidden HIV Burden

Surveillance suggests thousands may remain undiagnosed as late-stage presentations persist

The Pathologist

December 18, 2025

Can Prophylactic Radiation Prevent Complications of Bone Metastases in High-Risk, Asymptomatic Patients?

Some bone metastases appear to be at higher risk for such complications as pathologic fracture, spinal cord compression, pain or surgery to bone, even if they’re asymptomatic

Roswell Park Comprehensive Cancer Center